Listeria News and Research

RSS

Listeria is a bacterial genus containing seven species. Named after the English pioneer of sterile surgery, Joseph Lister, Listeria species are Gram-positive bacilli and are typified by ''L. monocytogenes'', the causative agent of listeriosis.

AOAC certifies InstantLabs Salmonella Species Food Safety Kit

InstantLabs Medical Diagnostics Corporation, developer of the portable Hunter Accelerated Real-Time PCR system, today announced that its Salmonella Species Food Safety Kit has been certified as AOAC Performance-Tested (AOAC PTM Cert. No. 031202) by the AOAC Research Institute (AOAC-RI) across four key food matrices.

19 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Trudeau Institute to receive sub-contract for translational research grant from NIH

The Trudeau Institute has announced it is the recipient of a sub-contract for a translational research grant from the National Institutes of Health.

12 Jun 2012

An Achilles heel within cells that bacteria exploit to cause infection

Scientists have discovered an Achilles heel within our cells that bacteria are able to exploit to cause and spread infection.

4 May 2012

InstantLabs receives PTM certification for Salmonella Species Food Safety Kit

InstantLabs Medical Diagnostics Corporation, developer of the portable Hunter Accelerated Real-Time PCR system, today announced that its Salmonella Species Food Safety Kit has been certified as Performance-Tested Methods (PTM) No. 031202 by the AOAC Research Institute.

3 Apr 2012

Risk of botulism at California fish processing company

The U.S. Food and Drug Administration, in a complaint filed by the Department of Justice, is seeking to stop the processing and distribution of fish products at a California company because of a risk of botulism and other food hazards.

30 Mar 2012

New antibiotic shows promise against bovine mastitis

Food-borne diseases might soon have another warrior to contend with, thanks to a new molecule discovered by chemists at the University of Illinois. The new antibiotic, an analog of the widely used food preservative nisin, also has potential to be a boon to the dairy industry as a treatment for bovine mastitis.

20 Mar 2012

Study finds traces of bacteria listeria in ready-to-eat fish products in Vancouver

A University of British Columbia study has found traces of the bacteria listeria in ready-to-eat fish products sold in Metro Vancouver, Canada.

28 Feb 2012

Clinical Cancer Research publishes results of Aduro's ANZ-100 and CRS-207 Phase 1 studies

Aduro BioTech, Inc. is pleased to announce the publication of two therapeutic cancer vaccine Phase 1 studies in Clinical Cancer Research. In the article, which was featured as one of the highlights of the issue, Dr. Dung Le et al. reported that intravenous administration of ANZ-100 and CRS-207 was well tolerated in subjects with advanced, treatment-refractory cancers.

7 Feb 2012

Third-party to prepare FDA submittals for NanoLogix

NanoLogix Inc., an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria announces that has instructed a third-party to prepare a total of six applications for submittal to the US FDA.

11 Jan 2012

Modified probiotics could one day decrease risk of Listeria infection

Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.

10 Jan 2012

Contaminated cantaloupes carrying listeria

According to federal health officials last week, at least 13 people are dead amid 72 sickened in 18 states in an outbreak of listeria food poisoning tied to contaminated cantaloupes.

8 Jan 2012

Roka raises $47.5M in Series D round

Roka Bioscience announced today that it has secured $47.5 million in Series D financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors, New Enterprise Associates, Inc., and TPG Biotech. In conjunction with the financing, Josh Bilenker, M.D., Partner at Aisling Capital, will join Roka's Board of Directors.

6 Jan 2012

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

Scientists discover how intestinal tract influences B cells to prevent infection

Researchers at the University of Toronto have found an explanation for how the intestinal tract influences a key component of the immune system to prevent infection, offering a potential clue to the cause of autoimmune disorders like rheumatoid arthritis and multiple sclerosis.

13 Dec 2011

Publicly posting enforcement and testing data on meat processing facilities could be beneficial

Publicly posting enforcement and testing data corresponding to specific meat, poultry, and egg products' processing plants on the Internet could have "substantial benefits," including the potential to favorably impact public health, says a new report from the National Research Council.

1 Dec 2011

Advaxis completes ADXS-HER2 pre-IND meeting with FDA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, completed a pre-IND meeting with the FDA on November 22, 2011 to discuss the development plan for ADXS-HER2, an immunotherapy for the treatment of HER2 expressing cancers.

23 Nov 2011

Advaxis licenses ISG15 tumor antigen from University of Pennsylvania

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.

16 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

UCB to present new data on Cimzia at ACG annual scientific meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.

1 Nov 2011